jotea personal page - To The Moon

jotea

jotea

No personal profile

5Follow

0Followers

0Topic

0Badge

2022-02-02

Reply?

GSK to get $1.25 bln to settle HIV drug patent row with Gilead

2022-02-02

Ok

7 Stocks To Watch For February 2, 2022

2021-06-15

Like comment

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586772923001410","uuid":"3586772923001410","gmtCreate":1623743837956,"gmtModify":1623746555601,"name":"jotea","pinyin":"jotea","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9091119342,"gmtCreate":1643799839942,"gmtModify":1676533857699,"author":{"id":"3586772923001410","authorId":"3586772923001410","name":"jotea","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586772923001410","idStr":"3586772923001410"},"themes":[],"htmlText":"Reply?","listText":"Reply?","text":"Reply?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091119342","repostId":"2208235710","repostType":4,"repost":{"id":"2208235710","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1643790588,"share":"https://ttm.financial/m/news/2208235710?lang=&edition=fundamental","pubTime":"2022-02-02 16:29","market":"us","language":"en","title":"GSK to get $1.25 bln to settle HIV drug patent row with Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2208235710","media":"Reuters","summary":"Feb 2 (Reuters) - Britain's GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as","content":"<html><head></head><body><p>Feb 2 (Reuters) - Britain&#39;s GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.</p><p>The settlement, announced by GSK on Tuesday, relates to Gilead&#39;s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare&#39;s dolutegravir and other similar compounds.</p><p>HIV medicines developed by ViiV, in which Pfizer    and Japan&#39;s Shionogi    also hold small stakes, are a major part of GSK&#39;s plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.</p><p>The payment is expected to be made in the first quarter this year, London-listed GSK said</p><p>Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.</p><p>The settlement weighed on Gilead&#39;s fourth-quarter results on Tuesday as its profit missed market expectations.</p><p>Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.</p><p>Gilead&#39;s Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK&#39;s ViiV and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Gilead&#39;s top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.</p><p>Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.</p><p>While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.</p><p>On Tuesday, U.S. regulators expanded the use of ViiV&#39;s Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK to get $1.25 bln to settle HIV drug patent row with Gilead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK to get $1.25 bln to settle HIV drug patent row with Gilead\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-02-02 16:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Feb 2 (Reuters) - Britain&#39;s GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.</p><p>The settlement, announced by GSK on Tuesday, relates to Gilead&#39;s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare&#39;s dolutegravir and other similar compounds.</p><p>HIV medicines developed by ViiV, in which Pfizer    and Japan&#39;s Shionogi    also hold small stakes, are a major part of GSK&#39;s plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.</p><p>The payment is expected to be made in the first quarter this year, London-listed GSK said</p><p>Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.</p><p>The settlement weighed on Gilead&#39;s fourth-quarter results on Tuesday as its profit missed market expectations.</p><p>Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.</p><p>Gilead&#39;s Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK&#39;s ViiV and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Gilead&#39;s top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.</p><p>Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.</p><p>While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.</p><p>On Tuesday, U.S. regulators expanded the use of ViiV&#39;s Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208235710","content_text":"Feb 2 (Reuters) - Britain's GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.The settlement, announced by GSK on Tuesday, relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.HIV medicines developed by ViiV, in which Pfizer    and Japan's Shionogi    also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.The payment is expected to be made in the first quarter this year, London-listed GSK saidGilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.The settlement weighed on Gilead's fourth-quarter results on Tuesday as its profit missed market expectations.Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.Gilead's Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK's ViiV and is one of Gilead's top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.On Tuesday, U.S. regulators expanded the use of ViiV's Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091110461,"gmtCreate":1643799783634,"gmtModify":1676533857667,"author":{"id":"3586772923001410","authorId":"3586772923001410","name":"jotea","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586772923001410","idStr":"3586772923001410"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091110461","repostId":"2208357786","repostType":4,"repost":{"id":"2208357786","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643795522,"share":"https://ttm.financial/m/news/2208357786?lang=&edition=fundamental","pubTime":"2022-02-02 17:52","market":"us","language":"en","title":"7 Stocks To Watch For February 2, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2208357786","media":"Benzinga","summary":"Some of the stocks that may grab inve3stor focus today are:\n","content":"<html><head></head><body><p>Some of the stocks that may grab inve3stor focus today are:</p><ul><li>Wall Street expects <b> Thermo Fisher Scientific Inc. </b> (NYSE:TMO) to report quarterly earnings at $5.26 per share on revenue of $9.29 billion before the opening bell. Thermo Fisher Scientific shares fell 1.5% to $585.50 in after-hours trading.</li><li>Analysts expect <b> <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, Inc. </b> (NASDAQ:FB) to report quarterly earnings at $3.84 per share on revenue of $33.38 billion after the closing bell. Meta Platforms shares rose 3.5% to $330.15 in after-hours trading.</li><li><b>Alphabet Inc. </b> (NASDAQ:GOOGL) reported better-than-expected results for its fourth quarter. The company’s board also approved a 20-for-1 stock split. Alphabet shares jumped 9.2% to $3,005.00 in the after-hours trading session.</li></ul><ul><li>Analysts are expecting <b> Humana Inc. </b> (NYSE:HUM) to have earned $1.16 per share on revenue of $21.23 billion for the latest quarter. The company will release earnings before the markets open. Humana shares rose 2% to $398.66 in after-hours trading.</li><li><b>General Motors Company </b> (NYSE:GM) reported better-than-expected earnings for its first quarter, while sales missed views. The company said it sees FY22 net income of $9.4 billion to $10.8 billion. GM shares gained 1.1% to $54.64 in the after-hours trading session.</li><li>Analysts expect <b> QUALCOMM Incorporated </b> (NASDAQ:QCOM) to post quarterly earnings at $3.01 per share on revenue of $10.42 billion after the closing bell. QUALCOMM shares gained 2.9% to $182.20 in after-hours trading.</li><li><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings, Inc.</b> (NASDAQ:PYPL) reported downbeat earnings for its fourth quarter and issued weak earnings forecast for FY22. PayPal shares dipped 17.9% to $144.30 in the after-hours trading session.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Stocks To Watch For February 2, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Stocks To Watch For February 2, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-02-02 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab inve3stor focus today are:</p><ul><li>Wall Street expects <b> Thermo Fisher Scientific Inc. </b> (NYSE:TMO) to report quarterly earnings at $5.26 per share on revenue of $9.29 billion before the opening bell. Thermo Fisher Scientific shares fell 1.5% to $585.50 in after-hours trading.</li><li>Analysts expect <b> <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, Inc. </b> (NASDAQ:FB) to report quarterly earnings at $3.84 per share on revenue of $33.38 billion after the closing bell. Meta Platforms shares rose 3.5% to $330.15 in after-hours trading.</li><li><b>Alphabet Inc. </b> (NASDAQ:GOOGL) reported better-than-expected results for its fourth quarter. The company’s board also approved a 20-for-1 stock split. Alphabet shares jumped 9.2% to $3,005.00 in the after-hours trading session.</li></ul><ul><li>Analysts are expecting <b> Humana Inc. </b> (NYSE:HUM) to have earned $1.16 per share on revenue of $21.23 billion for the latest quarter. The company will release earnings before the markets open. Humana shares rose 2% to $398.66 in after-hours trading.</li><li><b>General Motors Company </b> (NYSE:GM) reported better-than-expected earnings for its first quarter, while sales missed views. The company said it sees FY22 net income of $9.4 billion to $10.8 billion. GM shares gained 1.1% to $54.64 in the after-hours trading session.</li><li>Analysts expect <b> QUALCOMM Incorporated </b> (NASDAQ:QCOM) to post quarterly earnings at $3.01 per share on revenue of $10.42 billion after the closing bell. QUALCOMM shares gained 2.9% to $182.20 in after-hours trading.</li><li><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings, Inc.</b> (NASDAQ:PYPL) reported downbeat earnings for its fourth quarter and issued weak earnings forecast for FY22. PayPal shares dipped 17.9% to $144.30 in the after-hours trading session.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4561":"索罗斯持仓","BK4512":"苹果概念","GM":"通用汽车","BK4183":"个人用品","BK4209":"餐馆","BK4099":"汽车制造商","BOLT":"Bolt Biotherapeutics, Inc.","BK4514":"搜索引擎","OLPX":"Olaplex Holdings, Inc.","FWRG":"First Watch Restaurant Group, Inc.","BK4539":"次新股","BK4106":"数据处理与外包服务","TERN":"Terns Pharmaceuticals, Inc.","PYPL":"PayPal","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4191":"家用电器","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","HUM":"哈门那","TMO":"赛默飞世尔","BK4139":"生物科技","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","GOOG":"谷歌","BK4007":"制药","GOOGL":"谷歌A","HCTI":"Healthcare Triangle, Inc.","BK4566":"资本集团","BK4525":"远程办公概念","BK4535":"淡马锡持仓","BK4508":"社交媒体","BK4524":"宅经济概念","BK4121":"生命科学工具和服务","BK4167":"医疗保健技术","BK4077":"互动媒体与服务","BK4527":"明星科技股","BK4538":"云计算","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4141":"半导体产品","BK4154":"管理型保健护理","BK4503":"景林资产持仓","CRCT":"Cricut, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208357786","content_text":"Some of the stocks that may grab inve3stor focus today are:Wall Street expects  Thermo Fisher Scientific Inc.  (NYSE:TMO) to report quarterly earnings at $5.26 per share on revenue of $9.29 billion before the opening bell. Thermo Fisher Scientific shares fell 1.5% to $585.50 in after-hours trading.Analysts expect  Meta Platforms, Inc.  (NASDAQ:FB) to report quarterly earnings at $3.84 per share on revenue of $33.38 billion after the closing bell. Meta Platforms shares rose 3.5% to $330.15 in after-hours trading.Alphabet Inc.  (NASDAQ:GOOGL) reported better-than-expected results for its fourth quarter. The company’s board also approved a 20-for-1 stock split. Alphabet shares jumped 9.2% to $3,005.00 in the after-hours trading session.Analysts are expecting  Humana Inc.  (NYSE:HUM) to have earned $1.16 per share on revenue of $21.23 billion for the latest quarter. The company will release earnings before the markets open. Humana shares rose 2% to $398.66 in after-hours trading.General Motors Company  (NYSE:GM) reported better-than-expected earnings for its first quarter, while sales missed views. The company said it sees FY22 net income of $9.4 billion to $10.8 billion. GM shares gained 1.1% to $54.64 in the after-hours trading session.Analysts expect  QUALCOMM Incorporated  (NASDAQ:QCOM) to post quarterly earnings at $3.01 per share on revenue of $10.42 billion after the closing bell. QUALCOMM shares gained 2.9% to $182.20 in after-hours trading.PayPal Holdings, Inc. (NASDAQ:PYPL) reported downbeat earnings for its fourth quarter and issued weak earnings forecast for FY22. PayPal shares dipped 17.9% to $144.30 in the after-hours trading session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187378171,"gmtCreate":1623744596193,"gmtModify":1704210161099,"author":{"id":"3586772923001410","authorId":"3586772923001410","name":"jotea","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586772923001410","idStr":"3586772923001410"},"themes":[],"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187378171","repostId":"1130157766","repostType":4,"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9091119342,"gmtCreate":1643799839942,"gmtModify":1676533857699,"author":{"id":"3586772923001410","authorId":"3586772923001410","name":"jotea","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586772923001410","authorIdStr":"3586772923001410"},"themes":[],"htmlText":"Reply?","listText":"Reply?","text":"Reply?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091119342","repostId":"2208235710","repostType":4,"repost":{"id":"2208235710","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1643790588,"share":"https://ttm.financial/m/news/2208235710?lang=&edition=fundamental","pubTime":"2022-02-02 16:29","market":"us","language":"en","title":"GSK to get $1.25 bln to settle HIV drug patent row with Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2208235710","media":"Reuters","summary":"Feb 2 (Reuters) - Britain's GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as","content":"<html><head></head><body><p>Feb 2 (Reuters) - Britain&#39;s GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.</p><p>The settlement, announced by GSK on Tuesday, relates to Gilead&#39;s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare&#39;s dolutegravir and other similar compounds.</p><p>HIV medicines developed by ViiV, in which Pfizer    and Japan&#39;s Shionogi    also hold small stakes, are a major part of GSK&#39;s plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.</p><p>The payment is expected to be made in the first quarter this year, London-listed GSK said</p><p>Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.</p><p>The settlement weighed on Gilead&#39;s fourth-quarter results on Tuesday as its profit missed market expectations.</p><p>Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.</p><p>Gilead&#39;s Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK&#39;s ViiV and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Gilead&#39;s top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.</p><p>Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.</p><p>While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.</p><p>On Tuesday, U.S. regulators expanded the use of ViiV&#39;s Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK to get $1.25 bln to settle HIV drug patent row with Gilead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK to get $1.25 bln to settle HIV drug patent row with Gilead\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-02-02 16:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Feb 2 (Reuters) - Britain&#39;s GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.</p><p>The settlement, announced by GSK on Tuesday, relates to Gilead&#39;s antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare&#39;s dolutegravir and other similar compounds.</p><p>HIV medicines developed by ViiV, in which Pfizer    and Japan&#39;s Shionogi    also hold small stakes, are a major part of GSK&#39;s plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.</p><p>The payment is expected to be made in the first quarter this year, London-listed GSK said</p><p>Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.</p><p>The settlement weighed on Gilead&#39;s fourth-quarter results on Tuesday as its profit missed market expectations.</p><p>Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.</p><p>Gilead&#39;s Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK&#39;s ViiV and is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Gilead&#39;s top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.</p><p>Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.</p><p>While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.</p><p>On Tuesday, U.S. regulators expanded the use of ViiV&#39;s Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208235710","content_text":"Feb 2 (Reuters) - Britain's GlaxoSmithKline    will receive $1.25 billion from Gilead Sciences    as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.The settlement, announced by GSK on Tuesday, relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.HIV medicines developed by ViiV, in which Pfizer    and Japan's Shionogi    also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.The payment is expected to be made in the first quarter this year, London-listed GSK saidGilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.The settlement weighed on Gilead's fourth-quarter results on Tuesday as its profit missed market expectations.Shares of GSK were up 0.7% at 1,656p by 0821 GMT on Wednesday, while Gilead closed down 3.6% on Tuesday.Gilead's Biktarvy, which combines three HIV medicines in a single daily tablet, poses the biggest competitive challenge for GSK's ViiV and is one of Gilead's top selling treatments, bringing in sales of $7.05 billion in 2021 from the U.S. market.Cumulative U.S. sales of Biktarvy until 2027 are estimated to be about $50 billion, Jefferies analysts said, adding that royalties worth roughly 1.5 billion pounds ($2 billion) can be expected for ViiV overall.While Gilead is the leading supplier of HIV treatments, GSK has been working on challenging its dominance by focusing on longer-lasting treatments, like the two-drug regimen Dovato, to bring down the numbers of medicines patients have to take.On Tuesday, U.S. regulators expanded the use of ViiV's Cabenuva injection, taken once every two months, to include virologically suppressed adults with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091110461,"gmtCreate":1643799783634,"gmtModify":1676533857667,"author":{"id":"3586772923001410","authorId":"3586772923001410","name":"jotea","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586772923001410","authorIdStr":"3586772923001410"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091110461","repostId":"2208357786","repostType":4,"repost":{"id":"2208357786","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643795522,"share":"https://ttm.financial/m/news/2208357786?lang=&edition=fundamental","pubTime":"2022-02-02 17:52","market":"us","language":"en","title":"7 Stocks To Watch For February 2, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2208357786","media":"Benzinga","summary":"Some of the stocks that may grab inve3stor focus today are:\n","content":"<html><head></head><body><p>Some of the stocks that may grab inve3stor focus today are:</p><ul><li>Wall Street expects <b> Thermo Fisher Scientific Inc. </b> (NYSE:TMO) to report quarterly earnings at $5.26 per share on revenue of $9.29 billion before the opening bell. Thermo Fisher Scientific shares fell 1.5% to $585.50 in after-hours trading.</li><li>Analysts expect <b> <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, Inc. </b> (NASDAQ:FB) to report quarterly earnings at $3.84 per share on revenue of $33.38 billion after the closing bell. Meta Platforms shares rose 3.5% to $330.15 in after-hours trading.</li><li><b>Alphabet Inc. </b> (NASDAQ:GOOGL) reported better-than-expected results for its fourth quarter. The company’s board also approved a 20-for-1 stock split. Alphabet shares jumped 9.2% to $3,005.00 in the after-hours trading session.</li></ul><ul><li>Analysts are expecting <b> Humana Inc. </b> (NYSE:HUM) to have earned $1.16 per share on revenue of $21.23 billion for the latest quarter. The company will release earnings before the markets open. Humana shares rose 2% to $398.66 in after-hours trading.</li><li><b>General Motors Company </b> (NYSE:GM) reported better-than-expected earnings for its first quarter, while sales missed views. The company said it sees FY22 net income of $9.4 billion to $10.8 billion. GM shares gained 1.1% to $54.64 in the after-hours trading session.</li><li>Analysts expect <b> QUALCOMM Incorporated </b> (NASDAQ:QCOM) to post quarterly earnings at $3.01 per share on revenue of $10.42 billion after the closing bell. QUALCOMM shares gained 2.9% to $182.20 in after-hours trading.</li><li><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings, Inc.</b> (NASDAQ:PYPL) reported downbeat earnings for its fourth quarter and issued weak earnings forecast for FY22. PayPal shares dipped 17.9% to $144.30 in the after-hours trading session.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Stocks To Watch For February 2, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Stocks To Watch For February 2, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-02-02 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab inve3stor focus today are:</p><ul><li>Wall Street expects <b> Thermo Fisher Scientific Inc. </b> (NYSE:TMO) to report quarterly earnings at $5.26 per share on revenue of $9.29 billion before the opening bell. Thermo Fisher Scientific shares fell 1.5% to $585.50 in after-hours trading.</li><li>Analysts expect <b> <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, Inc. </b> (NASDAQ:FB) to report quarterly earnings at $3.84 per share on revenue of $33.38 billion after the closing bell. Meta Platforms shares rose 3.5% to $330.15 in after-hours trading.</li><li><b>Alphabet Inc. </b> (NASDAQ:GOOGL) reported better-than-expected results for its fourth quarter. The company’s board also approved a 20-for-1 stock split. Alphabet shares jumped 9.2% to $3,005.00 in the after-hours trading session.</li></ul><ul><li>Analysts are expecting <b> Humana Inc. </b> (NYSE:HUM) to have earned $1.16 per share on revenue of $21.23 billion for the latest quarter. The company will release earnings before the markets open. Humana shares rose 2% to $398.66 in after-hours trading.</li><li><b>General Motors Company </b> (NYSE:GM) reported better-than-expected earnings for its first quarter, while sales missed views. The company said it sees FY22 net income of $9.4 billion to $10.8 billion. GM shares gained 1.1% to $54.64 in the after-hours trading session.</li><li>Analysts expect <b> QUALCOMM Incorporated </b> (NASDAQ:QCOM) to post quarterly earnings at $3.01 per share on revenue of $10.42 billion after the closing bell. QUALCOMM shares gained 2.9% to $182.20 in after-hours trading.</li><li><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a> Holdings, Inc.</b> (NASDAQ:PYPL) reported downbeat earnings for its fourth quarter and issued weak earnings forecast for FY22. PayPal shares dipped 17.9% to $144.30 in the after-hours trading session.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4561":"索罗斯持仓","BK4512":"苹果概念","GM":"通用汽车","BK4183":"个人用品","BK4209":"餐馆","BK4099":"汽车制造商","BOLT":"Bolt Biotherapeutics, Inc.","BK4514":"搜索引擎","OLPX":"Olaplex Holdings, Inc.","FWRG":"First Watch Restaurant Group, Inc.","BK4539":"次新股","BK4106":"数据处理与外包服务","TERN":"Terns Pharmaceuticals, Inc.","PYPL":"PayPal","BK4515":"5G概念","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4191":"家用电器","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","HUM":"哈门那","TMO":"赛默飞世尔","BK4139":"生物科技","BK4555":"新能源车","BK4533":"AQR资本管理(全球第二大对冲基金)","GOOG":"谷歌","BK4007":"制药","GOOGL":"谷歌A","HCTI":"Healthcare Triangle, Inc.","BK4566":"资本集团","BK4525":"远程办公概念","BK4535":"淡马锡持仓","BK4508":"社交媒体","BK4524":"宅经济概念","BK4121":"生命科学工具和服务","BK4167":"医疗保健技术","BK4077":"互动媒体与服务","BK4527":"明星科技股","BK4538":"云计算","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4141":"半导体产品","BK4154":"管理型保健护理","BK4503":"景林资产持仓","CRCT":"Cricut, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208357786","content_text":"Some of the stocks that may grab inve3stor focus today are:Wall Street expects  Thermo Fisher Scientific Inc.  (NYSE:TMO) to report quarterly earnings at $5.26 per share on revenue of $9.29 billion before the opening bell. Thermo Fisher Scientific shares fell 1.5% to $585.50 in after-hours trading.Analysts expect  Meta Platforms, Inc.  (NASDAQ:FB) to report quarterly earnings at $3.84 per share on revenue of $33.38 billion after the closing bell. Meta Platforms shares rose 3.5% to $330.15 in after-hours trading.Alphabet Inc.  (NASDAQ:GOOGL) reported better-than-expected results for its fourth quarter. The company’s board also approved a 20-for-1 stock split. Alphabet shares jumped 9.2% to $3,005.00 in the after-hours trading session.Analysts are expecting  Humana Inc.  (NYSE:HUM) to have earned $1.16 per share on revenue of $21.23 billion for the latest quarter. The company will release earnings before the markets open. Humana shares rose 2% to $398.66 in after-hours trading.General Motors Company  (NYSE:GM) reported better-than-expected earnings for its first quarter, while sales missed views. The company said it sees FY22 net income of $9.4 billion to $10.8 billion. GM shares gained 1.1% to $54.64 in the after-hours trading session.Analysts expect  QUALCOMM Incorporated  (NASDAQ:QCOM) to post quarterly earnings at $3.01 per share on revenue of $10.42 billion after the closing bell. QUALCOMM shares gained 2.9% to $182.20 in after-hours trading.PayPal Holdings, Inc. (NASDAQ:PYPL) reported downbeat earnings for its fourth quarter and issued weak earnings forecast for FY22. PayPal shares dipped 17.9% to $144.30 in the after-hours trading session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187378171,"gmtCreate":1623744596193,"gmtModify":1704210161099,"author":{"id":"3586772923001410","authorId":"3586772923001410","name":"jotea","avatar":"https://static.tigerbbs.com/87c9a6b9d238e95bd23f3a95d6d2e939","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586772923001410","authorIdStr":"3586772923001410"},"themes":[],"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187378171","repostId":"1130157766","repostType":4,"repost":{"id":"1130157766","kind":"news","pubTimestamp":1623743342,"share":"https://ttm.financial/m/news/1130157766?lang=&edition=fundamental","pubTime":"2021-06-15 15:49","market":"us","language":"en","title":"Nvidia's Crypto Concerns Are Cancelled, Gaming To Reign Supreme","url":"https://stock-news.laohu8.com/highlight/detail?id=1130157766","media":"seekingalpha","summary":"Summary\n\nNvidia's massive FQ2 guidance raise brings bears (back) to the crypto talking point.\nBut if","content":"<p><b>Summary</b></p>\n<ul>\n <li>Nvidia's massive FQ2 guidance raise brings bears (back) to the crypto talking point.</li>\n <li>But if they move to crypto, they admit RTX 3000 series cards have been selling in droves - negating any paper launch theories.</li>\n <li>Management, though, is now becoming much more transparent with crypto revenue as it dives directly into the growing market.</li>\n <li>The market can now assess the at-risk revenue and understand the risk-adjusted return for Nvidia, which is why the stock has risen in the face of growing crypto revenue.</li>\n <li>There won't be any cannibalizing of Gaming division revenue as gamers will now take up the slack with RTX 30XX making up less than 4% of the market.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/00e894af87a4cdb30b9a1f647d2ee42d\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>StefaNikolic/E+ via Getty Images</span></p>\n<p>Another record quarter was put on the table just over two weeks ago when Nvidia (NVDA) announced even better revenue than even it anticipated&nbsp;in a late quarter update. But the guide was even more out of this world, showing analysts they're way off base in their models. This is causing the bears to move from one argument to another as each gets debunked through raw financial numbers. But now they're walking into a crypto debate where the bulls have more transparency and data on their side than any other time. Unfortunately, the crypto bear thesis is not the one to take this time around. Gaming revenue growth will not slow as there's a huge RTX 3000 series opportunity with less than 4% of the GPU market share, just as supply receives a much-needed reprieve with crypto migrating to a new SKU altogether. The market appreciates the mitigated risk with crypto revenue transparency, allowing the stock to sustain a premium valuation.</p>\n<p><b>Paper Launch, Remember?</b></p>\n<p>At first, the bears postulated the RTX 3000 series debut was a paper launch because there was such limited supply. Gamers across the internet were up in arms because so few cards could be bought, sold out everywhere. Limited supply has continued to plague the 3000 series since then.</p>\n<p>But Gaming revenue has gone from $1.65B before the RTX 3000 launch to $2.76B in the latest quarter, causing this bear talking point to fade over the last several months.</p>\n<p>If the 3000 cards were so limited in supply, what accounts for the consistent monstrous quarter-over-quarter growth in the Gaming division?</p>\n<p>Ah, I'm glad you asked.</p>\n<p>It's clearly the selling of more than just a few (paper) RTX 3000 cards.</p>\n<p><b>Crypto Is The Talking Point, Again</b></p>\n<p>That question brings us to the latest bear talking point - crypto. If the bears move to this point, they have given up on the paper launch argument. That's because to mine crypto, you need a powerful GPU, and that powerful GPU is an RTX 3000 series card. So either there are very few 3000 series being sold (paper launch) - which doesn't allow a crypto bubble to be an issue - or there are indeed enough 3000 cards to meaningfully show up on the top line and debate how much is due to crypto-related sales.</p>\n<p>But the crypto debate is much harder to prove for either side. Historically it has been a bit of a closed box in terms of what cards have been sold to crypto miners and which ones have gotten into \"real\" gamers' hands. The bears can point to this and say that whatever RTX 3000 series cards have been sold over the last several months were for crypto mining.</p>\n<p>And you might be wondering, \"Why is this a big deal? Revenue is revenue, regardless of who's buying the card.\"</p>\n<p>This might be true if it wasn't for the volatile nature of the cryptocurrency world. Mining crypto is a profitability equation of how high the hash rate of a processor is (how fast it can complete the crypto calculations on the blockchain to receive a reward) and how much that particular crypto is worth on the market. The higher the crypto price, the higher the incentive to mine (the reward is bigger in pure dollar terms).</p>\n<p>But in 2018, after the \"crypto bubble\" deflated when the price of Bitcoin (BTC-USD) and Ethereum (ETH-USD) plummeted 85% from then all-time highs, Nvidia's revenue took a hit. Suddenly the cards of 2018 were not profitable to mine at depressed prices. It appeared a lot of the Gaming division sales were tied to crypto, or at least enough to knock growth off-kilter. As a result, the company experienced negative top-line growth throughout the following year.</p>\n<p>This is why the word crypto spoken by management, along with the crypto volatility with Bitcoin and Ethereum 50% off the latest all-time highs, brings a shiver down the market's spine.</p>\n<p>It sees 2018 playing out all over again.</p>\n<p><b>Facing The Crypto Thesis Head On</b></p>\n<p>However, bulls have more data over the last two quarters than they did in the 2018 crypt bust, with the strongest talking point to date coming just a few weeks ago. That point is the new RTX 3000 SKUs which will physically limit the hash rate of the cards, deterring miners from buying cards and opening up supply to gamers for typical GPU use.</p>\n<p>But if crypto is a major part of Gaming division revenue and the company is going to hardware limit the hash rates to make them unprofitable to mine crypto, future Gaming revenue will undoubtedly suffer.</p>\n<p>Right?</p>\n<p>Apparently not; guidance isn't telling us that story. With the current quarter running from May through July and the&nbsp;new \"hash lite\" RTX cards shipping at the end of May, guidance was still $6.3B in revenue versus The Street consensus of $5.48B.</p>\n<p>The hidden gem in the guide was the additional data bulls have needed for some time: a breakdown of revenue from CMPs (crypto mining processors). The company created CMPs to serve the industrial crypto mining community to provide better performance (by focusing processing power specifically on hashing and removing graphic rendering capabilities) and separate the supply between miners and gamers. This works to benefit investors as this breakdown of revenue allows for better risk analysis of overall revenue.</p>\n<p>And that is the key to the crypto cycle this time around.</p>\n<p>The&nbsp;guide for FQ2 included $400M of revenue for CMP products&nbsp;(as shown under the OEM/Other category). You might see this as a huge risk (relative to overall revenue), but this has now made the risk a solid number. Before this CMP breakdown, the market and analysts had to rely on rough estimates based in wide ranges to understand how much the Gaming division had downside risk built into it due to crypto.</p>\n<p>Why has the market responded positively to the expected 158% quarter-over-quarter growth, which follows 114% sequential growth in the just reported quarter for CMP? Because the market can assess the risk to the downside now - uncertainty has been mitigated.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/10c92c645e86c40c1af4be579b56fab8\" tg-width=\"635\" tg-height=\"403\"><span>Data byYCharts</span></p>\n<p>The market knows $400M is the mark now. The rest of the divisions are more understood, and channel checks are more accurate there. The question mark has been crypto, and the company is now being the most transparent about it.</p>\n<p><b>Outlook For Gaming</b></p>\n<p>This then begs the question: how much will be cannibalized from the Gaming division?</p>\n<p>Not much if we continue doing the math on the FQ2 guide. After backing out the $400M of CMP sales, we're left with a guide of $5.9B. That's still $420M of outperformance analysts didn't account for, while the Gaming division will technically see two \"hits\" to its growth, each for the same reason. Not only is there a separate product line for crypto, but the RTX cards will also have their inherent mining performance throttled. This should provide no reason to continue using RTX cards as the best value for mining (relatively cheap compared to ASICs with still profitable processing power).</p>\n<p>Of course, not all of the $420M guidance raise is for Gaming. Still, considering it's the largest division with 48% of revenue in the last quarter, it stands that analysts will meaningfully raise estimates for the Gaming division.</p>\n<p>But then, where's the Gaming growth coming from in the quarters ahead?</p>\n<p>Gamers will be the clear demand driver now. Supply should now make its way toward the gamers who have been trying to get a 3000 series card for the last eight months. You don't have to Google very much to find folks still patiently - and impatiently - waiting for their 3000 series card.</p>\n<p>There's a huge runway for upgrades from prior RTX cards and GTX cards as the market penetration of RTX 30XX cards is still less than 4%, around 3.64%, according to Steam's monthly hardware survey. And that's growing each month since January across the SKU board. This compares to the current gamer market share of all other Nvidia cards of 68.6%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/828d8670b5f989162d31b002ead58ab0\" tg-width=\"640\" tg-height=\"109\"><span>(Source:Steam Hardware Survey)</span></p>\n<p>And if you're concerned about the lack of upgrades from RTX 20XX cards since they're only one generation behind, the non-RTX portion of the market makes up 55.11%. So there's a huge greenfield for upgrades to the 3000 series ahead with supply opening up to the real gamers.</p>\n<p><b>Outperformance To Continue</b></p>\n<p>Management has been tackling the market's concerns head-on, contrary to 2018. It has been able to capitalize on a strained crypto market because its GPU-based CMP processors are above and beyond anything anyone has ever produced. This time it did it correctly with much better transparency - the market appreciates the calculated risk.</p>\n<p>There's still further bullishness as Nvidia enters a crypto market dominated by ASICs, which tend to have very limited supply and very long lead times. Nvidia is capitalizing on the market using its larger contract position with fabs like Taiwan Semiconductor (TSM) and Samsung (OTC:SSNLF)(OTC:SSNNF) to produce competitive mining processors.</p>\n<p>Eventually, the transition of Ethereum (ETH-USD) to proof-of-stake from proof-of-work may serve as a headwind rather than a tailwind. Still, this risk is much further out as not only will the transition start in early 2022, but miners are expected to remain on the network&nbsp;for at least a year after the transition.</p>\n<p>It comes down to this: if the market has the data it needs to calculate the at-risk revenue easily, the market won't be as skittish to value Nvidia at the multiples it has grown to. Add in the huge upside to revenue for FQ2 with gamers now able to dive into the consumer market more fully, and you have a continuation for the Gaming division to outperform through at least year-end, if not well into 2022. For a long-term shareholder, there are further returns ahead for the stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia's Crypto Concerns Are Cancelled, Gaming To Reign Supreme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia's Crypto Concerns Are Cancelled, Gaming To Reign Supreme\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 15:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4434754-nvidias-crypto-concerns-are-cancelled-gaming-to-reign-supreme><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nNvidia's massive FQ2 guidance raise brings bears (back) to the crypto talking point.\nBut if they move to crypto, they admit RTX 3000 series cards have been selling in droves - negating any ...</p>\n\n<a href=\"https://seekingalpha.com/article/4434754-nvidias-crypto-concerns-are-cancelled-gaming-to-reign-supreme\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达"},"source_url":"https://seekingalpha.com/article/4434754-nvidias-crypto-concerns-are-cancelled-gaming-to-reign-supreme","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130157766","content_text":"Summary\n\nNvidia's massive FQ2 guidance raise brings bears (back) to the crypto talking point.\nBut if they move to crypto, they admit RTX 3000 series cards have been selling in droves - negating any paper launch theories.\nManagement, though, is now becoming much more transparent with crypto revenue as it dives directly into the growing market.\nThe market can now assess the at-risk revenue and understand the risk-adjusted return for Nvidia, which is why the stock has risen in the face of growing crypto revenue.\nThere won't be any cannibalizing of Gaming division revenue as gamers will now take up the slack with RTX 30XX making up less than 4% of the market.\n\nStefaNikolic/E+ via Getty Images\nAnother record quarter was put on the table just over two weeks ago when Nvidia (NVDA) announced even better revenue than even it anticipated in a late quarter update. But the guide was even more out of this world, showing analysts they're way off base in their models. This is causing the bears to move from one argument to another as each gets debunked through raw financial numbers. But now they're walking into a crypto debate where the bulls have more transparency and data on their side than any other time. Unfortunately, the crypto bear thesis is not the one to take this time around. Gaming revenue growth will not slow as there's a huge RTX 3000 series opportunity with less than 4% of the GPU market share, just as supply receives a much-needed reprieve with crypto migrating to a new SKU altogether. The market appreciates the mitigated risk with crypto revenue transparency, allowing the stock to sustain a premium valuation.\nPaper Launch, Remember?\nAt first, the bears postulated the RTX 3000 series debut was a paper launch because there was such limited supply. Gamers across the internet were up in arms because so few cards could be bought, sold out everywhere. Limited supply has continued to plague the 3000 series since then.\nBut Gaming revenue has gone from $1.65B before the RTX 3000 launch to $2.76B in the latest quarter, causing this bear talking point to fade over the last several months.\nIf the 3000 cards were so limited in supply, what accounts for the consistent monstrous quarter-over-quarter growth in the Gaming division?\nAh, I'm glad you asked.\nIt's clearly the selling of more than just a few (paper) RTX 3000 cards.\nCrypto Is The Talking Point, Again\nThat question brings us to the latest bear talking point - crypto. If the bears move to this point, they have given up on the paper launch argument. That's because to mine crypto, you need a powerful GPU, and that powerful GPU is an RTX 3000 series card. So either there are very few 3000 series being sold (paper launch) - which doesn't allow a crypto bubble to be an issue - or there are indeed enough 3000 cards to meaningfully show up on the top line and debate how much is due to crypto-related sales.\nBut the crypto debate is much harder to prove for either side. Historically it has been a bit of a closed box in terms of what cards have been sold to crypto miners and which ones have gotten into \"real\" gamers' hands. The bears can point to this and say that whatever RTX 3000 series cards have been sold over the last several months were for crypto mining.\nAnd you might be wondering, \"Why is this a big deal? Revenue is revenue, regardless of who's buying the card.\"\nThis might be true if it wasn't for the volatile nature of the cryptocurrency world. Mining crypto is a profitability equation of how high the hash rate of a processor is (how fast it can complete the crypto calculations on the blockchain to receive a reward) and how much that particular crypto is worth on the market. The higher the crypto price, the higher the incentive to mine (the reward is bigger in pure dollar terms).\nBut in 2018, after the \"crypto bubble\" deflated when the price of Bitcoin (BTC-USD) and Ethereum (ETH-USD) plummeted 85% from then all-time highs, Nvidia's revenue took a hit. Suddenly the cards of 2018 were not profitable to mine at depressed prices. It appeared a lot of the Gaming division sales were tied to crypto, or at least enough to knock growth off-kilter. As a result, the company experienced negative top-line growth throughout the following year.\nThis is why the word crypto spoken by management, along with the crypto volatility with Bitcoin and Ethereum 50% off the latest all-time highs, brings a shiver down the market's spine.\nIt sees 2018 playing out all over again.\nFacing The Crypto Thesis Head On\nHowever, bulls have more data over the last two quarters than they did in the 2018 crypt bust, with the strongest talking point to date coming just a few weeks ago. That point is the new RTX 3000 SKUs which will physically limit the hash rate of the cards, deterring miners from buying cards and opening up supply to gamers for typical GPU use.\nBut if crypto is a major part of Gaming division revenue and the company is going to hardware limit the hash rates to make them unprofitable to mine crypto, future Gaming revenue will undoubtedly suffer.\nRight?\nApparently not; guidance isn't telling us that story. With the current quarter running from May through July and the new \"hash lite\" RTX cards shipping at the end of May, guidance was still $6.3B in revenue versus The Street consensus of $5.48B.\nThe hidden gem in the guide was the additional data bulls have needed for some time: a breakdown of revenue from CMPs (crypto mining processors). The company created CMPs to serve the industrial crypto mining community to provide better performance (by focusing processing power specifically on hashing and removing graphic rendering capabilities) and separate the supply between miners and gamers. This works to benefit investors as this breakdown of revenue allows for better risk analysis of overall revenue.\nAnd that is the key to the crypto cycle this time around.\nThe guide for FQ2 included $400M of revenue for CMP products (as shown under the OEM/Other category). You might see this as a huge risk (relative to overall revenue), but this has now made the risk a solid number. Before this CMP breakdown, the market and analysts had to rely on rough estimates based in wide ranges to understand how much the Gaming division had downside risk built into it due to crypto.\nWhy has the market responded positively to the expected 158% quarter-over-quarter growth, which follows 114% sequential growth in the just reported quarter for CMP? Because the market can assess the risk to the downside now - uncertainty has been mitigated.\nData byYCharts\nThe market knows $400M is the mark now. The rest of the divisions are more understood, and channel checks are more accurate there. The question mark has been crypto, and the company is now being the most transparent about it.\nOutlook For Gaming\nThis then begs the question: how much will be cannibalized from the Gaming division?\nNot much if we continue doing the math on the FQ2 guide. After backing out the $400M of CMP sales, we're left with a guide of $5.9B. That's still $420M of outperformance analysts didn't account for, while the Gaming division will technically see two \"hits\" to its growth, each for the same reason. Not only is there a separate product line for crypto, but the RTX cards will also have their inherent mining performance throttled. This should provide no reason to continue using RTX cards as the best value for mining (relatively cheap compared to ASICs with still profitable processing power).\nOf course, not all of the $420M guidance raise is for Gaming. Still, considering it's the largest division with 48% of revenue in the last quarter, it stands that analysts will meaningfully raise estimates for the Gaming division.\nBut then, where's the Gaming growth coming from in the quarters ahead?\nGamers will be the clear demand driver now. Supply should now make its way toward the gamers who have been trying to get a 3000 series card for the last eight months. You don't have to Google very much to find folks still patiently - and impatiently - waiting for their 3000 series card.\nThere's a huge runway for upgrades from prior RTX cards and GTX cards as the market penetration of RTX 30XX cards is still less than 4%, around 3.64%, according to Steam's monthly hardware survey. And that's growing each month since January across the SKU board. This compares to the current gamer market share of all other Nvidia cards of 68.6%.\n(Source:Steam Hardware Survey)\nAnd if you're concerned about the lack of upgrades from RTX 20XX cards since they're only one generation behind, the non-RTX portion of the market makes up 55.11%. So there's a huge greenfield for upgrades to the 3000 series ahead with supply opening up to the real gamers.\nOutperformance To Continue\nManagement has been tackling the market's concerns head-on, contrary to 2018. It has been able to capitalize on a strained crypto market because its GPU-based CMP processors are above and beyond anything anyone has ever produced. This time it did it correctly with much better transparency - the market appreciates the calculated risk.\nThere's still further bullishness as Nvidia enters a crypto market dominated by ASICs, which tend to have very limited supply and very long lead times. Nvidia is capitalizing on the market using its larger contract position with fabs like Taiwan Semiconductor (TSM) and Samsung (OTC:SSNLF)(OTC:SSNNF) to produce competitive mining processors.\nEventually, the transition of Ethereum (ETH-USD) to proof-of-stake from proof-of-work may serve as a headwind rather than a tailwind. Still, this risk is much further out as not only will the transition start in early 2022, but miners are expected to remain on the network for at least a year after the transition.\nIt comes down to this: if the market has the data it needs to calculate the at-risk revenue easily, the market won't be as skittish to value Nvidia at the multiples it has grown to. Add in the huge upside to revenue for FQ2 with gamers now able to dive into the consumer market more fully, and you have a continuation for the Gaming division to outperform through at least year-end, if not well into 2022. For a long-term shareholder, there are further returns ahead for the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}